ENGOT-EN2 / DGCG
A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.
ISGO
MK-2870-005-ENGOT-en23
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
C93GOG-3064 ENGOT-en15
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
Trial Number
NCT05173987 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
GLORIOSA
Randomized, multicenter, open-label, phase 3 study of mirvetuximab
soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab
Trial Number
NCT05445778 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ENGOT-ov72/ROSELLA
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s Choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Trial Number
NCT05257408 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
SALVOVAR
A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor primary chemosensitivity and incomplete debulking surgery
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
FIRST-ENGOT-Ov44 (ENGOT/GCIG/Tesaro)
A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Trial Number
NCT03602859 (ClinicalTrials.gov ID)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
OReO-ENGOT-Ov38 (ENGOT/GCIG/AZ)
Phase III study Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer
Trial Number
NCT03106987 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ATALANTE
Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab
Trial Number
NCT02891824 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ANITA/ ENGOT-Ov41/ GEICO 69-O
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months